Amgen's Blincyto Data Send Cullinan Higher
Seeking Alpha15:39 ET
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
Yahoo FinanceApr 26 11:34 ET
Express News | Novartis Pharms Corp Gets FDA New Drug Application Approval For VIJOICE
BenzingaApr 25 11:09 ET
Novartis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/24/2024 18.83% BMO Capital $114 → $116 Maintains Market Perform 02/23/2024 16.78% BMO Capital → $114 In
BenzingaApr 24 11:02 ET
Company News for Apr 24, 2024
Yahoo FinanceApr 24 09:36 ET
Express News | Novartis AG : BMO Raises Target Price to $116 From $114
Moomoo 24/7Apr 24 06:51 ET
Express News | Novartis And Medicines For Malaria Venture Announced Data From Phase 2/3 CALINA Study, Demonstrating That Formulated Coartem Developed For Babies Weighing Less Than 5Kg With Malaria Has The Required Pharmacokinetic Profile, Good Efficacy, And Safety
Moomoo 24/7Apr 24 05:37 ET
Novartis Partnership Says New Malaria Drug for Babies Effective, Safe in Phase 2/3 Trial
Novartis (NOVN.SW) and the product development partnership Medicines for Malaria Venture on Wednesday said a new formula of malaria drug Coartem for babies showed "good" efficacy and safety in the pha
MT NewswiresApr 24 01:19 ET
Novartis Receives FDA Approval for Gastroenteropancreatic Tumor Treatment in Pediatric Patients
Novartis (NOVN.SW) received approval from the US Food and Drug Administration for its radioligand therapy Lutathera for pediatric patients aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.
MT NewswiresApr 23 23:53 ET
US Equity Markets Close Higher Tuesday
US equity markets ended higher Tuesday as investors assessed the latest batch of corporate earnings. * New-home sales rose to a 693,000 annual rate in March from a downwardly revised 637,000 rate in F
MT NewswiresApr 23 16:10 ET
Express News | NYSE Order Imbalance 82474.0 Shares on Sell Side
Moomoo 24/7Apr 23 15:50 ET
Novartis Radioligand Therapy Lutathera FDA Approved First Medicine Specifically For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic neuro
BenzingaApr 23 14:15 ET
Novartis Wins Pediatric Indication for Lutathera for Rare Cancer
Seeking AlphaApr 23 14:08 ET
Sanofi Reportedly Lining up Banks for Consumer Products Spinoff
Seeking AlphaApr 23 13:32 ET
Earnings Call Summary | Novartis AG(NVS.US) Q1 2024 Earnings Conference
The following is a summary of the Novartis AG (NVS) Q1 2024 Earnings Call Transcript:Financial Performance:Novartis reported Q1 2024 sales were up 11% in constant currencies.Core operating income incr
moomoo AIApr 23 13:07 ET · Conference Call
Research Alert: CFRA Keeps Hold Opinion On Adss Of Novartis Ag
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our target price by $3 to $108,
MT NewswiresApr 23 12:45 ET
Novartis Raises Full-year Guidance on Q1 Beat, Drug Sales
Yahoo FinanceApr 23 10:51 ET
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
Yahoo FinanceApr 23 09:44 ET
Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics
Yahoo FinanceApr 23 09:30 ET
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Health care stocks were steady pre-bell Tuesday with the iShares Biotechnology ETF (IBB) and Health Care Select Sector SPDR Fund (XLV) recently inactive. Danaher (DHR) rose past 6% after it reported l
MT NewswiresApr 23 09:04 ET
No Data
No Data